The stock of STAAR Surgical Company (NASDAQ:STAA) hit a new 52-week high and has $11.23 target or 4.00% above today’s $10.80 share price. The 7 months bullish chart indicates low risk for the $442.66 million company. The 1-year high was reported on Dec, 1 by Barchart.com. If the $11.23 price target is reached, the company will be worth $17.71 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. The stock decreased 0.46% or $0.05 during the last trading session, hitting $10.8. About 65,393 shares traded hands. STAAR Surgical Company (NASDAQ:STAA) has risen 41.28% since April 28, 2016 and is uptrending. It has outperformed by 35.35% the S&P500.
Analysts await STAAR Surgical Company (NASDAQ:STAA) to report earnings on March, 1.
According to Zacks Investment Research, “Staar Surgical Company has evolved to become a developer, manufacturer and global distributor of products used by ophthalmologists and other eye care professionals to improve or correct vision in patients suffering from refractive conditions, cataracts and glaucoma.”
Insitutional Activity: The institutional sentiment decreased to 1.17 in 2016 Q2. Its down 0.14, from 1.31 in 2016Q1. The ratio worsened, as 6 funds sold all STAAR Surgical Company shares owned while 20 reduced positions. 7 funds bought stakes while 27 increased positions. They now own 29.99 million shares or 0.42% less from 30.12 million shares in 2016Q1.
Teacher Retirement Sys Of Texas last reported 0% of its portfolio in the stock. The California-based California Public Employees Retirement has invested 0% in STAAR Surgical Company (NASDAQ:STAA). Prudential Fincl Inc has invested 0% of its portfolio in STAAR Surgical Company (NASDAQ:STAA). The New York-based Alliancebernstein Ltd Partnership has invested 0% in STAAR Surgical Company (NASDAQ:STAA). Metropolitan Life Ins holds 0% of its portfolio in STAAR Surgical Company (NASDAQ:STAA) for 29,550 shares. Reliance Tru Commerce Of Delaware owns 27,000 shares or 0.01% of their US portfolio. Weiss Multi holds 0.02% of its portfolio in STAAR Surgical Company (NASDAQ:STAA) for 40,095 shares. Creative Planning last reported 35,890 shares in the company. Teachers Advsrs last reported 0% of its portfolio in the stock. D E Shaw & Co Inc last reported 12,625 shares in the company. Commercial Bank Of America De accumulated 755 shares or 0% of the stock. Swiss Bank & Trust holds 62,400 shares or 0% of its portfolio. Grandeur Peak Global Ltd holds 0.86% or 582,861 shares in its portfolio. Nationwide Fund Advsr last reported 0% of its portfolio in the stock. State Street Corp last reported 585,085 shares in the company.
Insider Transactions: Since June 28, 2016, the stock had 1 buying transaction, and 0 sales for $74,081 net activity. 14,144 shares were bought by BROADWOOD PARTNERS LP, worth $74,081 on Tuesday, June 28.
More notable recent STAAR Surgical Company (NASDAQ:STAA) news were published by: Prnewswire.com which released: “STAAR Surgical Reports First Quarter 2016 Results” on May 11, 2016, also Prnewswire.com with their article: “STAAR Surgical to Report Third Quarter Results on November 3, 2016” published on October 20, 2016, Prnewswire.com published: “STAAR Surgical Announces Strategic Cooperation Agreement With World Eye …” on September 07, 2016. More interesting news about STAAR Surgical Company (NASDAQ:STAA) were released by: Prnewswire.com and their article: “STAAR Surgical Company and Memira Holding Announce Cooperation Agreement for …” published on February 09, 2016 as well as Prnewswire.com‘s news article titled: “STAAR Surgical Reports Second Quarter 2016 Results” with publication date: August 03, 2016.
STAA Company Profile
STAAR Surgical Company (STAAR), incorporated on April 3, 1986, designs, develops, makes and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The Firm operates in the ophthalmic surgical market segment. The Company’s principal products are intraocular lenses (IOLs) used in cataract surgery and implantable collamer lenses (ICLs) used in refractive surgery. The Firm makes lenses used across the world in corrective or refractive surgery, and makes lenses for use in surgery that treats cataracts. The Firm operates under the brands STAAR, Visian, Collamer, CentraFLOW, AquaPORT, nanoFLEX nanoPOINT, Epiphany and AquaFlow. Collamer is the brand name for STAAR’s collagen copolymer lens material. STAAR sells its products in approximately 60 countries, with direct distribution in the United States, Canada, Japan and Spain, and independent distribution in the remainder of the world.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.